Janssen Announces Tremfya Demonstrates Significant Skin Clearance In First-Of-Its-Kind Prospective, Large-Scale Study Dedicated To People Of Color Living With Moderate To Severe Plaque Psoriasis
Portfolio Pulse from Benzinga Newsdesk
Janssen, a pharmaceutical company of Johnson & Johnson (JNJ), announced that its drug Tremfya demonstrated significant skin clearance in a large-scale study dedicated to people of color living with moderate to severe plaque psoriasis. This is the first study of its kind.
October 20, 2023 | 2:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's subsidiary Janssen's drug Tremfya has shown significant results in a unique large-scale study. This could potentially boost JNJ's market share in the psoriasis treatment market.
The positive results from the study of Tremfya, a drug developed by JNJ's subsidiary Janssen, could potentially increase the demand for the drug. This could lead to an increase in JNJ's revenues and potentially its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100